Connect Biopharma Hires General Counsel & Chief Compliance Officer and Appoints a New Board Member
August 23 2021 - 4:05PM
Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect
Biopharma" or the “Company”), a global clinical-stage
biopharmaceutical company dedicated to improving the lives of
patients with chronic inflammatory diseases through the development
of therapies derived from T cell-driven research, today announced
Mr. Jiang Bian has joined the Company as General Counsel &
Chief Compliance Officer, effective August 20, 2021. In his role,
Mr. Bian will oversee Connect Biopharma’s legal function and will
report to Dr. Zheng Wei, Co-founder and CEO. The hiring of Mr. Bian
is an important step in filling out the Company’s Executive
Leadership and advancing the organizational growth strategy.
Separately, the Company announced a change to
the composition of its Board of Directors, with the appointment of
Jean Liu, J.D., Executive Vice President, Legal Affairs, General
Counsel and Secretary of Seagen Inc., a targeted cancer therapeutic
company. Ms. Liu joins as an Independent Director to the
Company.
“Jiang has strong experience both as a senior
counsel in healthcare and biopharmaceutical companies as well as at
a law firm representing global public companies and emerging life
science and technology companies in licensing, intellectual
property and corporate issues. He will be a key addition to our
executive management team as we continue our progress as newly
public company,” said Dr. Zheng Wei.
Mr. Bian joins Connect Biopharma from Guardant
Health, Inc., a publicly traded precision oncology diagnostics
company, based in Redwood City, California, where he served as
Senior Counsel. Prior to Guardant Health, Mr. Bian was with
Shartsis Friese LLP where he focused on corporate and
technology licensing areas of legal advisory. Mr. Bian also held
positions of increasing responsibility, including Senior Counsel at
Pieris Pharmaceuticals, Inc., a publicly traded biotechnology
company. He received his LL.B. from Southwest University of
Political Science and Law, Chongqing, China, and his LL.M. in
Intellectual Property and J.D. from George Washington University
Law School.
“I am thrilled to be joining Connect and lead
its global legal efforts as a part of a team that has made such
significant progress over the past 18 months and with their recent
IPO,” said Mr. Bian. “I look forward to working with Wei and the
whole Connect team to achieve even greater results.”
Commenting on the appointment to the Board, Dr.
Wubin Pan, Co-founder, President and Chairman of the Board, said,
“We are delighted to have Ms. Jean Liu join our Board of Directors
as we continue to deliver on our growth strategy. Jean is a highly
respected biotech executive with more than twenty years of
experience working with leading biotech companies in high-growth
transformations through her deep expertise across corporate
governance and strategic business transactions. Liu’s counsel will
be a welcomed addition to our Board.”
“Connect’s pipeline progress in developing novel
candidates targeting inflammatory diseases with high unmet medical
need has been truly impressive,” said Ms. Liu. “I am excited for
the opportunity to work closely with the team to continue Connect’s
successful growth trajectory.”
About Connect Biopharma Holdings
LimitedConnect Biopharma Holdings Limited is a global
clinical-stage biopharmaceutical company dedicated to improving the
lives of patients living with chronic inflammatory diseases through
the development of therapies derived from our T cell-driven
research.
Our lead product candidate, CBP-201, is an
antibody designed to target interleukin-4 receptor alpha (IL-4Rα)
and is currently being evaluated in clinical trials for the
treatment of atopic dermatitis (AD) and asthma and in development
for chronic rhinosinusitis with nasal polyps (CRSwNP). Our second
lead product candidate is CBP-307, a modulator of a T cell receptor
known as sphingosine 1-phosphate receptor 1 (S1P1) that is in
development for the treatment of ulcerative colitis (UC) and
Crohn’s disease (CD). Furthermore, we are developing CBP-174, a
peripherally restricted antagonist of histamine receptor 3, for the
treatment of pruritus associated with skin inflammation.
With headquarters in China, additional
operations in the United States and Australia, and clinical
development activities in those geographies as well as Europe,
Connect Biopharma is building a rich global pipeline of internally
designed, wholly owned small molecules and antibodies targeting
several aspects of T cell biology. For additional information about
Connect Biopharma, please visit our website at
www.connectbiopharm.com.
FORWARD-LOOKING STATEMENTS
Connect Biopharma cautions that statements
included in this press release that are not a description of
historical facts are forward-looking statements. Words such as
"may," "could," "will," "would," "should," "expect," "plan,"
"anticipate," "believe," "estimate," "intend," "predict," "seek,"
"contemplate," "potential," "continue" or "project" or the negative
of these terms or other comparable terminology are intended to
identify forward-looking statements. The inclusion of
forward-looking statements should not be regarded as a
representation by Connect Biopharma that any of its plans will be
achieved. Actual results may differ from those set forth in this
release due to the risks and uncertainties inherent in the Connect
Biopharma business and other risks described in the Company's
filings with the Securities and Exchange Commission ("SEC").
Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and Connect Biopharma undertakes no obligation to revise or update
this news release to reflect events or circumstances after the date
hereof. Further information regarding these and other risks is
included in Connect Biopharma's filings with the SEC which are
available from the SEC's website (www.sec.gov) and on Connect
Biopharma's website (www.connectbiopharm.com) under the heading
"Investors." All forward-looking statements are qualified in their
entirety by this cautionary statement. This caution is made under
the safe harbor provisions of Section 21E of the Private Securities
Litigation Reform Act of 1995.
IR/PR Contacts: Lazar FINN Partners David
Carey (IR) T: +1-(212)
867-1768david.carey@finnpartners.comErich Sandoval
(Media)T:
+1-(917)-497-2867erich.sandoval@finnpartners.com
Corporate
Contacts:info@connectpharm.com
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Apr 2023 to Apr 2024